Situs Kesehatan Terpercaya

Thursday, October 19, 2017

Hormone therapy for prostate cancer increases the risk of heart


Hormone therapy for prostate cancer increases the risk of heart - Androgen-deprivation therapy, which is a common treatment for prostate cancer, has been tentatively linked with an increased risk of cardiovascular disease. A new study solidifies these concerns.

Prostate cancer needs to testosterone for growth and prosperity, so the Androgen deprivation therapy (ADT) is designed to reduce the amount of testosterone in the body close to zero, which helps slow the growth of cancer.

Although the results are controversial, some studies have shown that combined with radiotherapy is more successful in treating prostate cancer than just radiation alone.

Currently, ADT is recommended for advanced prostate cancer. But it is increasingly used to treat local prostate cancer, although minimal evidence of its effectiveness.

At the same time, the number of cases of localized prostate cancer has increased dramatically in recent years, in part because of the widespread use of the prostate antigen test.

Side effects of ADT - including erectile dysfunction, diabetes, bone loss, swollen breast tissue, or gynecomastia - can be fairly large. In addition, there is increasing evidence suggesting that low levels of testosterone may increase the risk of cardiovascular disease (cardiovascular disease).

A difficult challenge for lead-hard links

Studies looking at links between cardiovascular disease and ADT multiple neuropathy have reached conflicting conclusions. For example, one meta-analysis found a 40 percent increase in the risk of non-fatal cardiovascular disease in men with prostate cancer who received a lead. On the other hand, a previous study found no link at all between lead and cardiovascular death.

It was therefore difficult for researchers, so far, to draw accurate lines between heart health and led.

Studies have faced a range of problems: some were primarily seen in older men, where heart conditions are more common, and some have not received information about other drugs that participants were taking.

Even when links are found, it is difficult to tell if led led cardiovascular disease or simply exacerbate the pre-existing heart condition.

A new study set out to rectify the issues experienced in previous studies. Led by Reina Haque, Ph.D., of Kaiser Permanente Southern California in Pasadena, their findings are published this month in the British Journal of Cancer.

The authors write, "[O]ur goal was to assess the association of ADT and important incident CVD outcomes in a cohort that also included younger men."

"We accounted," they add, "for important confounders, including prior CVD history, PSA levels, CVD medications, and CVD risk factors. Additionally, we assessed whether ADT only has effect on new-onset CVD or also on the progression of pre-existing cardiovascular conditions."

ADT Led to the risk of heart failure

In total, the study included 7,737 men who were recently diagnosed with localized prostate cancer. Of these men, about one-third (30 per cent) received massage therapy. They were followed up for a maximum of 13 years.

After controlling the above variables - as well as others including body mass index and smoking - individuals who have led and not existing cardiovascular disease increased the risk of 81 percent of heart failure.

Men with pre-existing cardiovascular disease patients experienced a 44 percent increase in the risk of arrhythmias. Similarly, the risk of conduction disorder - a problem with the way electrical pulses pass through the heart - is three times.

When discussing why the relationship between cardiovascular disease and lead may occur, researchers cover a range of potential factors.

First, testosterone deficiency increases fat mass, a risk factor for cardiovascular disease. Also, men with low testosterone levels are more likely to have abnormal fat profiles, increased levels of pro-inflammatory factors, and high blood pressure.

The authors hope the results could help identify prostate cancer patients who are at higher risk for cardiovascular disease. They can then be given regular cardiac tests, encouraged to exercise, and blood pressure and diabetes are closely monitored. QnC Jelly Gamat

Share on Facebook
Share on Twitter
Share on Google+
Tags :

Related : Hormone therapy for prostate cancer increases the risk of heart

0 comments:

Post a Comment